Authors' objectives: To undertake a systematic review on the effectiveness or efficacy, safety and cost effectiveness of using 10-valent and 13-valent pneumococcal conjugate vaccine.

Authors' recommendations: Thirty-six studies were included in this review, where one of the studies was a systematic review; one study was a heath technology assessment, eleven RCT's, three cross sectional studies and twenty economic evaluation studies. For efficacy/effectiveness, fourteen articles were included, whereby thirteen studies involved PCV13 as the main intervention, with only one study involving PCV 10 as the main intervention and only two studies directly comparing PCV13 and PCV10. For safety, nine articles were included, out of which eight studies had PCV 13 as the main intervention, with only one study that involved PCV 10 as the main intervention and only one study directly comparing PCV13 and PCV10. For cost effectiveness, twenty articles were included with twelve studies that included PCV 13 as the main intervention, six studies that involved PCV 10 as the main intervention while six studies were directly comparing PCV13 and PCV10. There was fair to good level of evidence to show that PCV7 is no longer cost effective because of increases in uinvasive diseases caused by nonvaccine serotypes, which reduces the overall direct effects of vaccination. The 10-valent and 13-valent pneumococcal vaccines showed better net health benefits than PCV7. Total programme costs can be lowered by reduction in vaccine prices. A national immunization program with PCV10 or PCV13 was estimated to prevent additional cases of disease among children and save additional costs due to treatment of acute otitis media (AOM) and pneumococcal diseases. Choosing between the PCV10 and PCV13 vaccines will depend on the preference of the decision maker either to prevent the severe invasive pneumococcal diseases (IPD) cases only, or prevention of AOM. There was fair to good level of evidence to show that PCV13 was predicted to provide a higher impact on IPD and CAP, while PCV10 was expected to provide a substantially greater reduction in AOM.

Project Status: Completed

Year Published: 2014

URL for published report: http://www.moh.gov.my/hta/HTA%20report%20-%20Pneumococcal%20Conjugate%20Vaccine%20for%20Children%20%20below%20Five%20years%20old.pdf

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Malaysia

Organisation Name: Malaysian Health Technology Assessment

Contact Address: Malaysian Health Technology Assessment Section, Ministry of Health Malaysia, Federal Government Administrative Centre, Level 4, Block E1, Parcel E, 62590 Putrajaya Malaysia Tel: +603 8883 1229

Contact Name: htamalaysia@moh.gov.my

Contact Email: htamalaysia@moh.gov.my

Copyright: Malaysian Health Technology Assessment (MaHTAS)